ambition

Quote




































The proof is in the stock, which has not changed for either company to a measurable dent since ambition was released last week. My customers have said that the edema is the only number that stands out about this study. They have also said that while 50% reduction appears big, it needed to be bigger after Seraphin. My center docs said that they will not change what they are doing and are comfortable using maci to start, add, or start with a PDE-5. No one from Actelion is threatened by this data. We will continue to own the ERA business while looking ahead to the launch of selexipeg. At that time, gilead-UT-Bayer can fight for our scraps. Thank you for being an admirable foe from March 4, 2011 until last November when Maci was launched. Ambition was your last rabbit out of the hat and it died in the hat! Thank you for playing...drive home safely. And in the future....stick to HIV where you belong.
 






Anonymous said:
The proof is in the stock, which has not changed for either company to a measurable dent since ambition was released last week. My customers have said that the edema is the only number that stands out about this study. They have also said that while 50% reduction appears big, it needed to be bigger after Seraphin. My center docs said that they will not change what they are doing and are comfortable using maci to start, add, or start with a PDE-5. No one from Actelion is threatened by this data. We will continue to own the ERA business while looking ahead to the launch of selexipeg. At that time, gilead-UT-Bayer can fight for our scraps. Thank you for being an admirable foe from March 4, 2011 until last November when Maci was launched. Ambition was your last rabbit out of the hat and it died in the hat! Thank you for playing...drive home safely. And in the future....stick to HIV where you belong.
Click to expand...

The stock hasn't changed?? I'll point out that we are up 40% in 2014. I think we will stick to HIV....and HCV....and oncology. My stock could pay for your home. And your spouse.
 












Anonymous said:
The proof is in the stock, which has not changed for either company to a measurable dent since ambition was released last week. My customers have said that the edema is the only number that stands out about this study. They have also said that while 50% reduction appears big, it needed to be bigger after Seraphin. My center docs said that they will not change what they are doing and are comfortable using maci to start, add, or start with a PDE-5. No one from Actelion is threatened by this data. We will continue to own the ERA business while looking ahead to the launch of selexipeg. At that time, gilead-UT-Bayer can fight for our scraps. Thank you for being an admirable foe from March 4, 2011 until last November when Maci was launched. Ambition was your last rabbit out of the hat and it died in the hat! Thank you for playing...drive home safely. And in the future....stick to HIV where you belong.
Click to expand...

Opsumit is NOT better than Letairis and sorry to tell you it has the same or more EDEMA - so be careful what you say. Keep telling docs to switch stable Tracleer patients to Maci so they keep failing and going on Letairis because you are telling them not to Rx Tracleer. You are helping us you fools.

Ambition was very positive and the data doesn't lie.
 






Top Bottom
Back
Quote